Posted by Michael Wonder on 26 Mar 2019
PHARMAC defends not funding expensive breast cancer drugs
26 March 2019 - PHARMAC is defending their decision not to fund certain breast cancer drugs.
For two weeks in a row now, women suffering from breast cancer have taken to parliament to plead for help.
They are looking to secure PHARMAC funding for several new breast cancer drugs - Ibrance and Kadcyla - that prolong life, but are currently very expensive in New Zealand.
